Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 177

  • The following term was not found in PubMed: Fetske.

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.

Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D.

Am J Transplant. 2019 Jul 1. doi: 10.1111/ajt.15514. [Epub ahead of print]


Transfusion of leukoreduced blood products and risk of antibody-mediated rejection of renal allografts.

Bynum JP, Zachary A, Ness PM, Luo X, Bagnasco S, King KE, Segev DL, Orandi BJ, Warren DS, Fuller A, Ciappi A, Montgomery R, Tobian AAR.

Transfusion. 2018 Aug;58(8):1951-1957. doi: 10.1111/trf.14800. Epub 2018 Sep 1.


HLA in transplantation.

Montgomery RA, Tatapudi VS, Leffell MS, Zachary AA.

Nat Rev Nephrol. 2018 Sep;14(9):558-570. doi: 10.1038/s41581-018-0039-x. Review.


Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.

Pinelli DF, Zachary AA, Friedewald JJ, Gjertson DW, Evans MA, Chatroop EN, Leffell MS, Vo AA, Jordan SC, Montgomery RA, Tambur AR.

Am J Transplant. 2019 Feb;19(2):381-390. doi: 10.1111/ajt.15007. Epub 2018 Aug 23.


Pre-transplant Screening for Non-HLA Antibodies: Who should be Tested?

Philogene MC, Zhou S, Lonze BE, Bagnasco S, Alasfar S, Montgomery RA, Kraus E, Jackson AM, Leffell MS, Zachary AA.

Hum Immunol. 2018 Apr;79(4):195-202. doi: 10.1016/j.humimm.2018.02.001. Epub 2018 Feb 8.


Editorial on histocompatibility section 2017.

Zachary AA, Leffell MS.

Curr Opin Organ Transplant. 2017 Aug;22(4):398-399. doi: 10.1097/MOT.0000000000000439. No abstract available.


HLA Mismatching Strategies for Solid Organ Transplantation - A Balancing Act.

Zachary AA, Leffell MS.

Front Immunol. 2016 Dec 7;7:575. doi: 10.3389/fimmu.2016.00575. eCollection 2016. Review.


Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.

Philogene MC, Bagnasco S, Kraus ES, Montgomery RA, Dragun D, Leffell MS, Zachary AA, Jackson AM.

Transplantation. 2017 Mar;101(3):608-615. doi: 10.1097/TP.0000000000001231.


Clinically relevant interpretation of solid phase assays for HLA antibody.

Bettinotti MP, Zachary AA, Leffell MS.

Curr Opin Organ Transplant. 2016 Aug;21(4):453-8. doi: 10.1097/MOT.0000000000000326. Review.


Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG.

N Engl J Med. 2016 Mar 3;374(9):896-8. doi: 10.1056/NEJMc1509268. No abstract available.


Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.

Orandi BJ, Alachkar N, Kraus ES, Naqvi F, Lonze BE, Lees L, Van Arendonk KJ, Wickliffe C, Bagnasco SM, Zachary AA, Segev DL, Montgomery RA.

Am J Transplant. 2016 Jan;16(1):213-20. doi: 10.1111/ajt.13434. Epub 2015 Aug 28.


Incidence and early outcomes associated with pre-transplant antivimentin antibodies in the cardiac transplantation population.

Young RK, Dale B, Russell SD, Zachary AA, Tedford RJ.

Clin Transplant. 2015 Aug;29(8):685-8. doi: 10.1111/ctr.12567. Epub 2015 Jun 17.


HLA high-resolution typing for sensitized patients: a solution in search of a problem?

Cecka JM, Reed EF, Zachary AA.

Am J Transplant. 2015 Apr;15(4):855-6. doi: 10.1111/ajt.13169. Epub 2015 Mar 16. No abstract available.


Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response.

Lucas DP, Leffell MS, Zachary AA.

Transplantation. 2015 Jan;99(1):77-85. doi: 10.1097/TP.0000000000000355.


Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.

Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA.

Transplantation. 2014 Oct 27;98(8):857-63. doi: 10.1097/TP.0000000000000298.


A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.

Jackson AM, Kraus ES, Orandi BJ, Segev DL, Montgomery RA, Zachary AA.

Kidney Int. 2015 Feb;87(2):409-16. doi: 10.1038/ki.2014.261. Epub 2014 Jul 23.


Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.

Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, Kraus E, Rabb H, Zachary AA, Montgomery RA, Alachkar N.

Transplantation. 2014 Jun 27;97(12):1240-6. doi: 10.1097/01.TP.0000442503.85766.91.


Quantifying the risk of incompatible kidney transplantation: a multicenter study.

Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Gaber AO, Montgomery RA, Segev DL.

Am J Transplant. 2014 Jul;14(7):1573-80. doi: 10.1111/ajt.12786. Epub 2014 Jun 9.


Differential effect of bortezomib on HLA class I and class II antibody.

Philogene MC, Sikorski P, Montgomery RA, Leffell MS, Zachary AA.

Transplantation. 2014 Sep 27;98(6):660-5. doi: 10.1097/TP.0000000000000132.


The role of donor-specific HLA alloantibodies in liver transplantation.

O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, Klintmalm GB.

Am J Transplant. 2014 Apr;14(4):779-87. doi: 10.1111/ajt.12667. Epub 2014 Mar 1.

Supplemental Content

Loading ...
Support Center